These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 31713024)

  • 1. Novel DDX41 variants in Thai patients with myeloid neoplasms.
    Polprasert C; Takeda J; Niparuck P; Rattanathammethee T; Pirunsarn A; Suksusut A; Kobbuaklee S; Wudhikarn K; Lawasut P; Kongkiatkamon S; Chuncharunee S; Songserm K; Phowthongkum P; Bunworasate U; Nannya Y; Yoshida K; Makishima H; Ogawa S; Rojnuckarin P
    Int J Hematol; 2020 Feb; 111(2):241-246. PubMed ID: 31713024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique ethnic features of
    Choi EJ; Cho YU; Hur EH; Jang S; Kim N; Park HS; Lee JH; Lee KH; Kim SH; Hwang SH; Seo EJ; Park CJ; Lee JH
    Haematologica; 2022 Feb; 107(2):510-518. PubMed ID: 33626862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
    Quesada AE; Routbort MJ; DiNardo CD; Bueso-Ramos CE; Kanagal-Shamanna R; Khoury JD; Thakral B; Zuo Z; Yin CC; Loghavi S; Ok CY; Wang SA; Tang Z; Bannon SA; Benton CB; Garcia-Manero G; Kantarjian H; Luthra R; Medeiros LJ; Patel KP
    Am J Hematol; 2019 Jul; 94(7):757-766. PubMed ID: 30963592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms.
    Alkhateeb HB; Nanaa A; Viswanatha D; Foran JM; Badar T; Sproat L; He R; Nguyen P; Jevremovic D; Salama ME; Greipp P; Gangat N; Tefferi A; Litzow MR; Mangaonkar AA; Shah MV; Patnaik M; Al-Kali A
    Blood Adv; 2022 Jan; 6(2):528-532. PubMed ID: 34644397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline DDX41 mutations define a significant entity within adult MDS/AML patients.
    Sébert M; Passet M; Raimbault A; Rahmé R; Raffoux E; Sicre de Fontbrune F; Cerrano M; Quentin S; Vasquez N; Da Costa M; Boissel N; Dombret H; Peffault de Latour R; Socié G; Itzykson R; Fenaux P; Soulier J; Adès L; Clappier E
    Blood; 2019 Oct; 134(17):1441-1444. PubMed ID: 31484648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.
    Li P; Brown S; Williams M; White T; Xie W; Cui W; Peker D; Lei L; Kunder CA; Wang HY; Murray SS; Vagher J; Kovacsovics T; Patel JL
    Blood; 2022 Aug; 140(7):716-755. PubMed ID: 35671390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.
    Badar T; Chlon T
    Curr Hematol Malig Rep; 2022 Oct; 17(5):113-120. PubMed ID: 35781188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing.
    Maierhofer A; Mehta N; Chisholm RA; Hutter S; Baer C; Nadarajah N; Pohlkamp C; Thompson ER; James PA; Kern W; Haferlach C; Meggendorfer M; Haferlach T; Blombery P
    Blood Adv; 2023 Dec; 7(23):7346-7357. PubMed ID: 37874914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral Blood and Bone Marrow Findings in Treatment-Naive Patients With Cytopenia(s)/Myeloid Neoplasms Harboring Both a Germline and a Somatic DDX41 Mutation.
    Bruehl FK; Elbaz Younes I; Bosler DS; Kelemen K; Jiang L; Reichard KK
    Appl Immunohistochem Mol Morphol; 2024 Sep; 32(8):371-381. PubMed ID: 39046192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
    Bataller A; Loghavi S; Gerstein Y; Bazinet A; Sasaki K; Chien KS; Hammond D; Montalban-Bravo G; Borthakur G; Short N; Issa GC; Kadia TM; Daver N; Tang G; Quesada A; Patel KP; Ravandi F; Fiskus W; Mill CP; Kantarjian HM; Bhalla K; Garcia-Manero G; Oran B; DiNardo CD
    Am J Hematol; 2023 Nov; 98(11):1780-1790. PubMed ID: 37665752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
    Makishima H; Saiki R; Nannya Y; Korotev S; Gurnari C; Takeda J; Momozawa Y; Best S; Krishnamurthy P; Yoshizato T; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Nagata Y; Kakiuchi N; Onizuka M; Chiba K; Tanaka H; Kon A; Ochi Y; Nakagawa MM; Okuda R; Mori T; Yoda A; Itonaga H; Miyazaki Y; Sanada M; Ishikawa T; Chiba S; Tsurumi H; Kasahara S; Müller-Tidow C; Takaori-Kondo A; Ohyashiki K; Kiguchi T; Matsuda F; Jansen JH; Polprasert C; Blombery P; Kamatani Y; Miyano S; Malcovati L; Haferlach T; Kubo M; Cazzola M; Kulasekararaj AG; Godley LA; Maciejewski JP; Ogawa S
    Blood; 2023 Feb; 141(5):534-549. PubMed ID: 36322930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid neoplasms with germline DDX41 mutation.
    Cheah JJC; Hahn CN; Hiwase DK; Scott HS; Brown AL
    Int J Hematol; 2017 Aug; 106(2):163-174. PubMed ID: 28547672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and significance of DDX41 gene variants in the general population.
    Cheloor Kovilakam S; Gu M; Dunn WG; Marando L; Barcena C; Nik-Zainal S; Mohorianu I; Kar SP; Fabre MA; Quiros PM; Vassiliou GS
    Blood; 2023 Oct; 142(14):1185-1192. PubMed ID: 37506341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DDX41-related myeloid neoplasia.
    Maciejewski JP; Padgett RA; Brown AL; Müller-Tidow C
    Semin Hematol; 2017 Apr; 54(2):94-97. PubMed ID: 28637623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and molecular correlates of somatic and germline
    Badar T; Nanaa A; Foran JM; Viswanatha D; Al-Kali A; Lasho T; Finke C; Alkhateeb HB; He R; Gangat N; Shah M; Tefferi A; Mangaonkar AA; Litzow MR; Ongie LJ; Chlon T; Ferrer A; Patnaik MM
    Haematologica; 2023 Nov; 108(11):3033-3043. PubMed ID: 37199125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies.
    Lewinsohn M; Brown AL; Weinel LM; Phung C; Rafidi G; Lee MK; Schreiber AW; Feng J; Babic M; Chong CE; Lee Y; Yong A; Suthers GK; Poplawski N; Altree M; Phillips K; Jaensch L; Fine M; D'Andrea RJ; Lewis ID; Medeiros BC; Pollyea DA; King MC; Walsh T; Keel S; Shimamura A; Godley LA; Hahn CN; Churpek JE; Scott HS
    Blood; 2016 Feb; 127(8):1017-23. PubMed ID: 26712909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Pathologic Spectrum of DDX41-Mutated Hematolymphoid Neoplasms.
    Goyal T; Tu ZJ; Wang Z; Cook JR
    Am J Clin Pathol; 2021 Oct; 156(5):829-838. PubMed ID: 33929502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putative new childhood leukemia cancer predisposition syndrome caused by germline bi-allelic missense mutations in DDX41.
    Diness BR; Risom L; Frandsen TL; Hansen B; Andersen MK; Schmiegelow K; Wadt KAW
    Genes Chromosomes Cancer; 2018 Dec; 57(12):670-674. PubMed ID: 30144193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report.
    Shin WY; Yoon SY; Park R; Kim JA; Song HH; Bang HI; Won JH; Kim J
    BMC Med Genomics; 2022 Mar; 15(1):46. PubMed ID: 35246110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DDX41: the poster child for familial MDS/AML grows up.
    Truong P; Pimanda JE
    Blood; 2023 Feb; 141(5):447-449. PubMed ID: 36729548
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.